XML 69 R50.htm IDEA: XBRL DOCUMENT
v3.21.1

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Apr. 04, 2021 | Mar. 29, 2020
Sales by segment of business |  |
Sales to customers | $ 22,321 | $ 20,691
Percent Change (as a percent) | 7.90% |
U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 11,111 | 10,699
Percent Change (as a percent) | 3.90% |
International |  |
Sales by segment of business |  |
Sales to customers | $ 11,210 | 9,992
Percent Change (as a percent) | 12.20% |
Consumer Health |  |
Sales by segment of business |  |
Sales to customers | $ 3,543 | 3,625
Percent Change (as a percent) | (2.30%) |
Consumer Health | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,611 | 1,740
Percent Change (as a percent) | (7.40%) |
Consumer Health | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,932 | 1,885
Percent Change (as a percent) | 2.50% |
Consumer Health | OTC |  |
Sales by segment of business |  |
Sales to customers | $ 1,175 | 1,348
Percent Change (as a percent) | (12.90%) |
Consumer Health | OTC | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 599 | 689
Percent Change (as a percent) | (13.00%) |
Consumer Health | OTC | International |  |
Sales by segment of business |  |
Sales to customers | $ 575 | 659
Percent Change (as a percent) | (12.80%) |
Consumer Health | Skin Health/Beauty |  |
Sales by segment of business |  |
Sales to customers | $ 1,163 | 1,117
Percent Change (as a percent) | 4.10% |
Consumer Health | Skin Health/Beauty | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 634 | 659
Percent Change (as a percent) | (3.90%) |
Consumer Health | Skin Health/Beauty | International |  |
Sales by segment of business |  |
Sales to customers | $ 529 | 458
Percent Change (as a percent) | 15.70% |
Consumer Health | Oral Care |  |
Sales by segment of business |  |
Sales to customers | $ 417 | 395
Percent Change (as a percent) | 5.70% |
Consumer Health | Oral Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 163 | 176
Percent Change (as a percent) | (7.20%) |
Consumer Health | Oral Care | International |  |
Sales by segment of business |  |
Sales to customers | $ 254 | 219
Percent Change (as a percent) | 16.00% |
Consumer Health | Baby Care |  |
Sales by segment of business |  |
Sales to customers | $ 389 | 361
Percent Change (as a percent) | 7.70% |
Consumer Health | Baby Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 96 | 92
Percent Change (as a percent) | 4.20% |
Consumer Health | Baby Care | International |  |
Sales by segment of business |  |
Sales to customers | $ 293 | 269
Percent Change (as a percent) | 8.90% |
Consumer Health | Women's Health |  |
Sales by segment of business |  |
Sales to customers | $ 222 | 232
Percent Change (as a percent) | (4.30%) |
Consumer Health | Women's Health | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3 | 4
Percent Change (as a percent) | (25.80%) |
Consumer Health | Women's Health | International |  |
Sales by segment of business |  |
Sales to customers | $ 219 | 228
Percent Change (as a percent) | (3.90%) |
Consumer Health | Wound Care/Other |  |
Sales by segment of business |  |
Sales to customers | $ 177 | 171
Percent Change (as a percent) | 3.30% |
Consumer Health | Wound Care/Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 115 | 119
Percent Change (as a percent) | (3.00%) |
Consumer Health | Wound Care/Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 61 | 52
Percent Change (as a percent) | 17.60% |
PHARMACEUTICAL |  |
Sales by segment of business |  |
Sales to customers | $ 12,199 | 11,134
Percent Change (as a percent) | 9.60% |
PHARMACEUTICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 6,446 | 6,061
Percent Change (as a percent) | 6.40% |
PHARMACEUTICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 5,753 | 5,073
Percent Change (as a percent) | 13.40% |
PHARMACEUTICAL | Immunology |  |
Sales by segment of business |  |
Sales to customers | $ 3,914 | 3,638
Percent Change (as a percent) | 7.60% |
PHARMACEUTICAL | Immunology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 2,413 | 2,410
Percent Change (as a percent) | 0.10% |
PHARMACEUTICAL | Immunology | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,501 | 1,228
Percent Change (as a percent) | 22.30% |
PHARMACEUTICAL | Immunology | REMICADE® |  |
Sales by segment of business |  |
Sales to customers | $ 777 | 990
Percent Change (as a percent) | (21.50%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 489 | 625
Percent Change (as a percent) | (21.70%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |
Sales by segment of business |  |
Sales to customers | $ 57 | 110
Percent Change (as a percent) | (48.40%) |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |
Sales by segment of business |  |
Sales to customers | $ 232 | 256
Percent Change (as a percent) | (9.40%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |
Sales by segment of business |  |
Sales to customers | $ 562 | 529
Percent Change (as a percent) | 6.20% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 255 | 272
Percent Change (as a percent) | (5.90%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 307 | 258
Percent Change (as a percent) | 18.90% |
PHARMACEUTICAL | Immunology | STELARA® |  |
Sales by segment of business |  |
Sales to customers | $ 2,148 | 1,819
Percent Change (as a percent) | 18.10% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,331 | 1,217
Percent Change (as a percent) | 9.40% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 817 | 603
Percent Change (as a percent) | 35.60% |
PHARMACEUTICAL | Immunology | TREMFYA® |  |
Sales by segment of business |  |
Sales to customers | $ 418 | 296
Percent Change (as a percent) | 41.00% |
PHARMACEUTICAL | Immunology | TREMFYA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 274 | 187
Percent Change (as a percent) | 46.30% |
PHARMACEUTICAL | Immunology | TREMFYA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 143 | 109
Percent Change (as a percent) | 32.00% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 8 | 3
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | 7 | 0
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 2 | 3
Percent Change (as a percent) | (38.40%) |
PHARMACEUTICAL | Infectious Diseases |  |
Sales by segment of business |  |
Sales to customers | $ 1,007 | 920
Percent Change (as a percent) | 9.50% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 512 | 436
Percent Change (as a percent) | 17.40% |
PHARMACEUTICAL | Infectious Diseases | International |  |
Sales by segment of business |  |
Sales to customers | $ 494 | 483
Percent Change (as a percent) | 2.30% |
PHARMACEUTICAL | Infectious Diseases | COVID-19 |  |
Sales by segment of business |  |
Sales to customers | $ 100 | 0
PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S. |  |
Sales by segment of business |  |
Sales to customers | 100 | 0
PHARMACEUTICAL | Infectious Diseases | COVID-19 | International |  |
Sales by segment of business |  |
Sales to customers | 0 | 0
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |
Sales by segment of business |  |
Sales to customers | $ 243 | 224
Percent Change (as a percent) | 8.60% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 10 | 12
Percent Change (as a percent) | (12.30%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |
Sales by segment of business |  |
Sales to customers | $ 233 | 212
Percent Change (as a percent) | 9.80% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |
Sales by segment of business |  |
Sales to customers | $ 546 | 579
Percent Change (as a percent) | (5.80%) |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 380 | 396
Percent Change (as a percent) | (3.80%) |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 166 | 184
Percent Change (as a percent) | (9.90%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |
Sales by segment of business |  |
Sales to customers | $ 117 | 116
Percent Change (as a percent) | 0.60% |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 21 | 29
Percent Change (as a percent) | (27.00%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |
Sales by segment of business |  |
Sales to customers | $ 96 | 87
Percent Change (as a percent) | 9.70% |
PHARMACEUTICAL | Neuroscience |  |
Sales by segment of business |  |
Sales to customers | $ 1,721 | 1,658
Percent Change (as a percent) | 3.80% |
PHARMACEUTICAL | Neuroscience | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 771 | 748
Percent Change (as a percent) | 3.20% |
PHARMACEUTICAL | Neuroscience | International |  |
Sales by segment of business |  |
Sales to customers | $ 949 | 910
Percent Change (as a percent) | 4.30% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate |  |
Sales by segment of business |  |
Sales to customers | $ 171 | 171
Percent Change (as a percent) | 0.20% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 47 | 52
Percent Change (as a percent) | (9.60%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International |  |
Sales by segment of business |  |
Sales to customers | $ 123 | 118
Percent Change (as a percent) | 4.50% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |
Sales by segment of business |  |
Sales to customers | $ 965 | 883
Percent Change (as a percent) | 9.40% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 589 | 544
Percent Change (as a percent) | 8.30% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 376 | 339
Percent Change (as a percent) | 11.00% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |
Sales by segment of business |  |
Sales to customers | $ 157 | 170
Percent Change (as a percent) | (7.90%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 67 | 76
Percent Change (as a percent) | (11.80%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 89 | 94
Percent Change (as a percent) | (4.80%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |
Sales by segment of business |  |
Sales to customers | $ 428 | 435
Percent Change (as a percent) | (1.50%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 67 | 75
Percent Change (as a percent) | (9.80%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |
Sales by segment of business |  |
Sales to customers | $ 361 | 360
Percent Change (as a percent) | 0.20% |
PHARMACEUTICAL | Oncology |  |
Sales by segment of business |  |
Sales to customers | $ 3,570 | 3,013
Percent Change (as a percent) | 18.50% |
PHARMACEUTICAL | Oncology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,377 | 1,175
Percent Change (as a percent) | 17.20% |
PHARMACEUTICAL | Oncology | International |  |
Sales by segment of business |  |
Sales to customers | $ 2,193 | 1,839
Percent Change (as a percent) | 19.30% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |
Sales by segment of business |  |
Sales to customers | $ 1,365 | 937
Percent Change (as a percent) | 45.60% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 691 | 463
Percent Change (as a percent) | 49.20% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |
Sales by segment of business |  |
Sales to customers | $ 674 | 474
Percent Change (as a percent) | 42.20% |
PHARMACEUTICAL | Oncology | ERLEADA |  |
Sales by segment of business |  |
Sales to customers | $ 261 | 143
Percent Change (as a percent) | 82.80% |
PHARMACEUTICAL | Oncology | ERLEADA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 171 | 119
Percent Change (as a percent) | 44.00% |
PHARMACEUTICAL | Oncology | ERLEADA | International |  |
Sales by segment of business |  |
Sales to customers | $ 90 | 24
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |
Sales by segment of business |  |
Sales to customers | $ 1,125 | 1,031
Percent Change (as a percent) | 9.00% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 444 | 432
Percent Change (as a percent) | 2.80% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 680 | 599
Percent Change (as a percent) | 13.50% |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate |  |
Sales by segment of business |  |
Sales to customers | $ 638 | 690
Percent Change (as a percent) | (7.60%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 50 | 139
Percent Change (as a percent) | (64.20%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International |  |
Sales by segment of business |  |
Sales to customers | $ 588 | 552
Percent Change (as a percent) | 6.60% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) |  |
Sales by segment of business |  |
Sales to customers | $ 182 | 212
Percent Change (as a percent) | (14.20%) |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 21 | 22
Percent Change (as a percent) | (5.10%) |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | International |  |
Sales by segment of business |  |
Sales to customers | $ 161 | 190
Percent Change (as a percent) | (15.30%) |
PHARMACEUTICAL | Pulmonary Hypertension |  |
Sales by segment of business |  |
Sales to customers | $ 861 | 745
Percent Change (as a percent) | 15.50% |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 573 | 486
Percent Change (as a percent) | 18.00% |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |
Sales by segment of business |  |
Sales to customers | $ 288 | 260
Percent Change (as a percent) | 10.80% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |
Sales by segment of business |  |
Sales to customers | $ 450 | 389
Percent Change (as a percent) | 15.60% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 272 | 229
Percent Change (as a percent) | 18.50% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |
Sales by segment of business |  |
Sales to customers | $ 179 | 160
Percent Change (as a percent) | 11.50% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |
Sales by segment of business |  |
Sales to customers | $ 305 | 250
Percent Change (as a percent) | 22.00% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 259 | 212
Percent Change (as a percent) | 21.90% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |
Sales by segment of business |  |
Sales to customers | $ 46 | 38
Percent Change (as a percent) | 23.00% |
PHARMACEUTICAL | Pulmonary Hypertension | Other |  |
Sales by segment of business |  |
Sales to customers | $ 105 | 106
Percent Change (as a percent) | (0.60%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 42 | 44
Percent Change (as a percent) | (3.50%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 63 | 62
Percent Change (as a percent) | 1.40% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |
Sales by segment of business |  |
Sales to customers | $ 1,127 | 1,160
Percent Change (as a percent) | (2.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 799 | 806
Percent Change (as a percent) | (0.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 328 | 354
Percent Change (as a percent) | (7.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |
Sales by segment of business |  |
Sales to customers | $ 589 | 527
Percent Change (as a percent) | 11.70% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 589 | 527
Percent Change (as a percent) | 11.70% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |
Sales by segment of business |  |
Sales to customers | $ 150 | 175
Percent Change (as a percent) | (14.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 87 | 117
Percent Change (as a percent) | (26.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |
Sales by segment of business |  |
Sales to customers | $ 63 | 58
Percent Change (as a percent) | 9.20% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |
Sales by segment of business |  |
Sales to customers | $ 127 | 155
Percent Change (as a percent) | (18.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 62 | 76
Percent Change (as a percent) | (18.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |
Sales by segment of business |  |
Sales to customers | $ 64 | 79
Percent Change (as a percent) | (18.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other |  |
Sales by segment of business |  |
Sales to customers | $ 261 | 302
Percent Change (as a percent) | (13.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 60 | 85
Percent Change (as a percent) | (28.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 201 | 217
Percent Change (as a percent) | (7.70%) |
MEDICAL DEVICES |  |
Sales by segment of business |  |
Sales to customers | $ 6,579 | 5,932
Percent Change (as a percent) | 10.90% |
MEDICAL DEVICES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3,054 | 2,898
Percent Change (as a percent) | 5.40% |
MEDICAL DEVICES | International |  |
Sales by segment of business |  |
Sales to customers | $ 3,525 | 3,034
Percent Change (as a percent) | 16.20% |
MEDICAL DEVICES | Interventional Solutions |  |
Sales by segment of business |  |
Sales to customers | $ 949 | 727
Percent Change (as a percent) | 30.40% |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 434 | 365
Percent Change (as a percent) | 19.00% |
MEDICAL DEVICES | Interventional Solutions | International |  |
Sales by segment of business |  |
Sales to customers | $ 514 | 362
Percent Change (as a percent) | 42.00% |
MEDICAL DEVICES | Orthopaedics |  |
Sales by segment of business |  |
Sales to customers | $ 2,113 | 2,038
Percent Change (as a percent) | 3.70% |
MEDICAL DEVICES | Orthopaedics | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,249 | 1,250
Percent Change (as a percent) | (0.10%) |
MEDICAL DEVICES | Orthopaedics | International |  |
Sales by segment of business |  |
Sales to customers | $ 864 | 788
Percent Change (as a percent) | 9.70% |
MEDICAL DEVICES | Orthopaedics | HIPS |  |
Sales by segment of business |  |
Sales to customers | $ 357 | 337
Percent Change (as a percent) | 5.80% |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 210 | 206
Percent Change (as a percent) | 2.40% |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |
Sales by segment of business |  |
Sales to customers | $ 146 | 132
Percent Change (as a percent) | 11.20% |
MEDICAL DEVICES | Orthopaedics | KNEES |  |
Sales by segment of business |  |
Sales to customers | $ 317 | 343
Percent Change (as a percent) | (7.60%) |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 185 | 214
Percent Change (as a percent) | (13.50%) |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |
Sales by segment of business |  |
Sales to customers | $ 132 | 130
Percent Change (as a percent) | 2.00% |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |
Sales by segment of business |  |
Sales to customers | $ 733 | 654
Percent Change (as a percent) | 12.10% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 450 | 407
Percent Change (as a percent) | 10.70% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |
Sales by segment of business |  |
Sales to customers | $ 282 | 247
Percent Change (as a percent) | 14.40% |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 706 | 703
Percent Change (as a percent) | 0.40% |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 403 | 423
Percent Change (as a percent) | (4.80%) |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 303 | 280
Percent Change (as a percent) | 8.40% |
MEDICAL DEVICES | Surgery |  |
Sales by segment of business |  |
Sales to customers | $ 2,372 | 2,100
Percent Change (as a percent) | 12.90% |
MEDICAL DEVICES | Surgery | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 898 | 844
Percent Change (as a percent) | 6.50% |
MEDICAL DEVICES | Surgery | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,474 | 1,257
Percent Change (as a percent) | 17.30% |
MEDICAL DEVICES | Surgery | ADVANCED |  |
Sales by segment of business |  |
Sales to customers | $ 1,118 | 948
Percent Change (as a percent) | 18.00% |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 405 | 381
Percent Change (as a percent) | 6.50% |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |
Sales by segment of business |  |
Sales to customers | $ 713 | 567
Percent Change (as a percent) | 25.70% |
MEDICAL DEVICES | Surgery | GENERAL |  |
Sales by segment of business |  |
Sales to customers | $ 1,254 | 1,153
Percent Change (as a percent) | 8.80% |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 493 | 463
Percent Change (as a percent) | 6.50% |
MEDICAL DEVICES | Surgery | GENERAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 761 | 690
Percent Change (as a percent) | 10.30% |
MEDICAL DEVICES | Vision |  |
Sales by segment of business |  |
Sales to customers | $ 1,145 | 1,067
Percent Change (as a percent) | 7.30% |
MEDICAL DEVICES | Vision | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 472 | 439
Percent Change (as a percent) | 7.40% |
MEDICAL DEVICES | Vision | International |  |
Sales by segment of business |  |
Sales to customers | $ 673 | 628
Percent Change (as a percent) | 7.30% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 857 | 814
Percent Change (as a percent) | 5.30% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 371 | 346
Percent Change (as a percent) | 7.20% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 486 | 467
Percent Change (as a percent) | 4.00% |
MEDICAL DEVICES | Vision | SURGICAL |  |
Sales by segment of business |  |
Sales to customers | $ 288 | 253
Percent Change (as a percent) | 13.70% |
MEDICAL DEVICES | Vision | SURGICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 101 | 93
Percent Change (as a percent) | 8.20% |
MEDICAL DEVICES | Vision | SURGICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 187 | $ 160
Percent Change (as a percent) | 17.00% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |